Vanda Pharmaceuticals Inc. (VNDA) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
VNDA Revenue Growth
Revenue Breakdown (FY 2025)
VNDA's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
VNDA Revenue Analysis (2014–2025)
As of May 8, 2026, Vanda Pharmaceuticals Inc. (VNDA) generated trailing twelve-month (TTM) revenue of $217.8 million, reflecting modest growth of +3.4% year-over-year. The most recent quarter (Q1 2026) recorded $51.7 million in revenue, down 9.6% sequentially.
Looking at the longer-term picture, VNDA's 5-year compound annual growth rate (CAGR) stands at -2.7%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $268.7 million in 2021.
Revenue diversification analysis shows VNDA's business is primarily driven by Fanapt (62%), and Hetlioz (38%). With over half of revenue concentrated in Fanapt, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including SUPN (+16.3% YoY), PTCT (-53.3% YoY), and ACAD (+9.9% YoY), VNDA has underperformed the peer group in terms of revenue growth. Compare VNDA vs SUPN →
VNDA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| VNDACurrent | $218M | +3.4% | -2.7% | -70.0% | |
 SUPN | $719M | +16.3% | +6.7% | -5.1% | |
 PTCT | $1.7B | -53.3% | +35.4% | 49.5% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 PCRX | $726M | +4.6% | +11.1% | 4.6% |
VNDA Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $216.1M | +8.7% | $203.1M | 94.0% | $-151,168,000 | -70.0% |
| 2024 | $198.8M | +3.2% | $187.5M | 94.3% | $-40,660,000 | -20.5% |
| 2023 | $192.6M | -24.3% | $177.8M | 92.3% | $-13,952,000 | -7.2% |
| 2022 | $254.4M | -5.3% | $230.1M | 90.5% | $6.3M | 2.5% |
| 2021 | $268.7M | +8.3% | $243.1M | 90.5% | $42.2M | 15.7% |
| 2020 | $248.2M | +9.2% | $224.8M | 90.6% | $27.2M | 11.0% |
| 2019 | $227.2M | +17.6% | $202.7M | 89.2% | $22.8M | 10.0% |
| 2018 | $193.1M | +17.0% | $172.6M | 89.4% | $21.7M | 11.3% |
| 2017 | $165.1M | +13.1% | $147.2M | 89.2% | $-16,903,000 | -10.2% |
| 2016 | $146.0M | +32.8% | $121.3M | 83.1% | $-18,571,000 | -12.7% |
See VNDA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VNDA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VNDA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonVNDA — Frequently Asked Questions
Quick answers to the most common questions about buying VNDA stock.
Is VNDA's revenue growth accelerating or slowing?
VNDA revenue growth slowed to +3.4%, below the 5-year CAGR of -2.7%. TTM revenue is $218M. The deceleration marks a shift from historical growth rates.
What is VNDA's long-term revenue growth rate?
Vanda Pharmaceuticals Inc.'s 5-year revenue CAGR of -2.7% reflects the variable expansion pattern. Current YoY growth of +3.4% is near this long-term average.
How is VNDA's revenue distributed by segment?
VNDA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.